§01 Browse › Tesamorelin

Tesamorelin

Egrifta Egrifta SV
Research Compound
Growth hormone Fat loss

This profile covers Tesamorelin. Start with the peptide's intended use, human evidence and product-quality limitations before the mechanism details.

Technical catalog description

Tesamorelin is a stabilized GHRH analogue and one of the few GH-axis peptides with a real pharmaceutical identity rather than a pure research-peptide reputation. It stimulates pituitary GH release and downstream IGF-1 strongly enough to be clinically relevant, and it is best known for reducing visceral fat in the HIV lipodystrophy setting where it was originally developed.

In performance circles, tesamorelin gets attention from users who want a more legitimate GHRH option and care specifically about midsection fat distribution, waistline trend, and GH-axis support without the appetite spike and rougher feel common to the GHRP side of the family.

Overview Use context Comparison Safety
Warning
Can worsen glucose control in susceptible users · Raises IGF-1 and can bring edema or carpal-tunnel-like symptoms if pushed too hard · Best thought of as a visceral-fat tool, not a general shortcut to dramatic fat loss

Read next

Intro to Peptides 6 min readThe Philosophy and Practice of Harm Reduction 9 min readInjection Basics and Site Safety 13 min read
Overview

Tesamorelin stands out because it is an actual prescription GHRH analogue, not just another grey-market peptide people talk up on forums. The practical reason it gets attention is pretty specific: it has a real visceral-fat use case, and that is a different conversation from the usual “GH peptides for recovery and recomposition” pitch.

It also sits on a different part of the spectrum than compounds like GHRP-2 or Ipamorelin. Tesamorelin is less about chasing a noticeable pulse and more about using a cleaner, more pharmaceutical GH-axis signal for a slower body-composition objective.

Safety & monitoring
Side effects

  • Injection-site irritation, edema, joint tightness, and numb-hand or carpal-tunnel-like symptoms in some users

  • Higher fasting glucose or worse glucose tolerance if the user is already metabolically fragile

Monitoring

  • fasting glucose / HbA1c

  • IGF-1

  • waist circumference and bodyweight trend

  • edema or hand numbness

Avoid if

  • Poor glucose control without monitoring

  • Users expecting fast subcutaneous fat loss or a dramatic GH feel from a once-daily GHRH analogue

Use context

People choose tesamorelin when they want a GHRH analogue with a stronger legitimacy story and a clearer target than most peptide stacks. The appeal is usually central fat distribution, waistline trend, and visceral-fat reduction rather than trying to force a dramatic muscle-building effect out of a peptide.

Timeline & expectations

This is a slow compound. If it works, the feedback is usually gradual change in waistline, body-composition trend, and sometimes a general sense that recovery is a bit better. It is not the kind of peptide that usually produces a loud day-to-day effect.

Common mistakes

The biggest mistake is treating tesamorelin like a generic fat-loss peptide and expecting rapid visible change. The second is pushing the dose around as if more must be better, when the real issues tend to be glucose tolerance, edema, and whether the user even has a visceral-fat problem worth targeting in the first place.

Comparison notes

Compared with Ipamorelin or GHRP-2, tesamorelin is less about appetite or pulse feel and more about a specific visceral-fat use case. Compared with CJC-1295, it has a more pharmaceutical identity and a narrower practical role. Compared with direct hGH, it is usually milder, less dramatic, and more dependent on whether visceral fat is actually the problem being targeted.

Record quantities in the builder Read: Intro to Peptides ← Browse